Amplia Therapeutics Ltd
ATX
Company Profile
Business description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways: VEGFR3 and FLT3.
Contact
350 Queen Street
Level 17
MelbourneVIC3000
AUST: +61 391231140
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
Stocks News & Analysis
stocks
ASX listed bank overvalued despite strong earnings
Profit beats drive shares higher for Australia’s largest asset manager.
stocks
After earnings, is Amazon a buy, a sell, or fairly valued?
After the launch of Amazon Supply Chain Services, here’s what we think of the stock.
stocks
ASX retail share expected to recover despite choppy conditions
Weakening consumer demand a temporary headwind for ASX retailer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,928.60 | 0.70 | 0.01% |
| CAC 40 | 8,112.57 | 89.51 | -1.09% |
| DAX 40 | 24,338.63 | 324.98 | -1.32% |
| Dow JONES (US) | 49,609.16 | 12.19 | 0.02% |
| FTSE 100 | 10,233.07 | 43.88 | -0.43% |
| HKSE | 26,348.65 | 45.06 | -0.17% |
| NASDAQ | 26,247.08 | 440.88 | 1.71% |
| Nikkei 225 | 62,605.76 | 107.89 | -0.17% |
| NZX 50 Index | 13,177.50 | 2.37 | 0.02% |
| S&P 500 | 7,398.93 | 61.82 | 0.84% |
| S&P/ASX 200 | 8,689.20 | 1.10 | -0.01% |
| SSE Composite Index | 4,219.13 | 39.18 | 0.94% |